LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
86.88
+0.53 (+0.61%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close86.35
Open86.13
Bid85.49 x 800
Ask88.19 x 1800
Day's Range86.10 - 87.27
52 Week Range73.69 - 89.09
Volume5,575,197
Avg. Volume3,951,396
Market Cap88.677B
Beta0.25
PE Ratio (TTM)81.20
EPS (TTM)1.07
Earnings DateJul 24, 2018
Forward Dividend & Yield2.25 (2.63%)
Ex-Dividend Date2018-05-16
1y Target Est90.78
Trade prices are not sourced from all markets
  • Eli Lilly CEO: 'It's time for a change' in the drug prici...
    CNBC Videos4 days ago

    Eli Lilly CEO: 'It's time for a change' in the drug prici...

    Eli Lilly CEO Dave Ricks speaks with CNBC's Meg Tirrell about the current state of drug pricing.

  • Eli Lilly, Electronic Arts, PayPal, Palo Alto Networks & ...
    CNBC Videos6 days ago

    Eli Lilly, Electronic Arts, PayPal, Palo Alto Networks & ...

    The "Halftime Report" traders give their top stocks to watch for the second half.

  • Cramer: Eli Lilly's share price recovery symbolizes this ...
    CNBC Videos6 days ago

    Cramer: Eli Lilly's share price recovery symbolizes this ...

    Jim Cramer connects the recent action in Eli Lilly's stock with how analysts are interpreting the market layout.

  • Market attitude seen in Eli Lilly's share price recovery
    CNBC Videos6 days ago

    Market attitude seen in Eli Lilly's share price recovery

    Jim Cramer connects the recent action in Eli Lilly's stock with how analysts are interpreting the market layout.

  • Better Buy: Johnson & Johnson vs. Eli Lilly
    Motley Fool20 hours ago

    Better Buy: Johnson & Johnson vs. Eli Lilly

    Which of these big pharma stocks has a better chance to outperform for your portfolio.

  • Teva Scraps A Study In Cluster Headaches — And This Rival Benefits
    Investor's Business Daily3 days ago

    Teva Scraps A Study In Cluster Headaches — And This Rival Benefits

    Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks3 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • CNBC3 days ago

    Eli Lilly CEO: 'It's time for a change' in the drug pricing system

    Ricks says pharmacy benefit managers, or PBMs, are benefiting from price increases. "With the adoption of high-deductible plans, patients are subjected to the list price," said Ricks, who was in Minneapolis for the Piper Jaffray Heartland Summit, an annual health-care conference.

  • Should You Be Tempted To Sell Eli Lilly and Company (NYSE:LLY) Because Of Its PE Ratio?
    Simply Wall St.4 days ago

    Should You Be Tempted To Sell Eli Lilly and Company (NYSE:LLY) Because Of Its PE Ratio?

    Eli Lilly and Company (NYSE:LLY) trades with a trailing P/E of 79.9x, which is higher than the industry average of 23.5x. While LLY might seem like a stock to avoidRead More...

  • Reuters5 days ago

    Lilly's lupus treatment succeeds in mid-stage trial

    Eli Lilly & Co said on Wednesday its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year. The data come two weeks after U.S. health regulators approved the drug, baricitinib, under the trade name Olumiant, with a far more restrictive label than expected to treat rheumatoid arthritis. There are few available treatments for lupus, which affects multiple organs and tissues in the body, causing symptoms that range from extreme fatigue and unexplained fever to joint pain and rash.

  • J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit
    Zacks5 days ago

    J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit

    Johnson & Johnson (JNJ) to sell its LifeScan diabetes device unit to Platinum Equity.

  • The Wall Street Journal5 days ago

    [$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials

    AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.

  • TheStreet.com6 days ago

    Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

    have discontinued late-stage trials of their experimental Alzheimer's disease drug lanabecestat, sending both companies' stock prices down Tuesday. AstraZeneca's stock fell 22 cents to close at $36.16 a share, while Lilly dropped 35 cents to $85.49. "The complexity of Alzheimer's disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from the devastating disease," Dr. Daniel Skovronsky, president of Lilly Research Labs, said in the statement.

  • AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap
    Investor's Business Daily6 days ago

    AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap

    AstraZeneca and Eli Lilly became the latest Tuesday in a series of firms to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.

  • AstraZeneca, Lilly halt tests of experimental Alzheimer's treatment
    American City Business Journals6 days ago

    AstraZeneca, Lilly halt tests of experimental Alzheimer's treatment

    An independent data monitoring committee concluded the new drug candidate would not meet the desired endpoint in two late-stage clinical trials.

  • Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
    Zacks6 days ago

    Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

    Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

  • Alzheimer's Research Stumbles Again: What's the Road Ahead?
    Zacks6 days ago

    Alzheimer's Research Stumbles Again: What's the Road Ahead?

    The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

  • Reuters6 days ago

    Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

    Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease. The treatment, lanabecestat, belongs to a class of drugs called beta secretase cleaving enzyme (BACE) inhibitor, that blocks an enzyme involved in the production of a protein that creates brain plaques, considered a major cause of the disease. Experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures, with Johnson and Johnson last month stopping mid-stage trials testing its BACE inhibitor drug.

  • Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests
    Bloomberg6 days ago

    Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests

    Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness. An independent data monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.

  • Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
    PR Newswire6 days ago

    Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease

    INDIANAPOLIS, June 12, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on recommendations by an independent data monitoring committee (IDMC) which concluded that both the AMARANTH trial, in early Alzheimer's disease, and the DAYBREAK-ALZ trial, in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility. As a result of this decision, the related AMARANTH extension trial will also be discontinued.

  • Financial Times6 days ago

    [$$] AstraZeneca and Eli Lilly scrap Alzheimer’s drug trial

    AstraZeneca and Eli Lilly are to halt a global trial of a drug meant to treat people suffering from early and mild forms of Alzheimer’s disease after a panel found the treatment was unlikely to meet its ...

  • TheStreet.com6 days ago

    Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

    Typically, they would be held back by the gravitational pull of profit-takers and of the intrusion of higher rates or politics or weaker business. Price target boosting and research defenses and insurgents trying to make things happen. Let's go over all three starting with the target boost.

  • CNBC6 days ago

    Cramer Remix: What Trump’s endgame with China could really be about

    "Mad Money" host Jim Cramer breaks down President Trump's strategy on trade and why he has taken a hard stance with China. Cramer also reverses his stance on Jack Dorsey, the CEO of Twitter and Square. In the lightning round, Cramer warns against investing in a home security stock.

  • CNBC6 days ago

    Cramer: Eli Lilly's share price recovery symbolizes this market's attitude

    The recent action in Eli Lilly's stock speaks to how analysts are interpreting the market layout, "Mad Money" host Jim Cramer says. While markets were tepid on Monday ahead of a historic summit between the United States and North Korea, CNBC's Jim Cramer noticed a separate pattern taking hold on Wall Street. Cramer pointed to Eli Lilly LLY .

  • AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer
    Zacks7 days ago

    AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

    AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.